TBPH icon

Theravance Biopharma

84 hedge funds and large institutions have $1.31B invested in Theravance Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more funds holding

Funds holding:

more first-time investments, than exits

New positions opened: | Existing positions closed:

less ownership

Funds ownership:

19% less capital invested

Capital invested by funds: $1.62B → $1.31B (-$312M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

100% less call options, than puts

Call options by funds: $2K | Put options by funds: $944K

Holders
84
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$2K
Puts
$944K
Net Calls
Net Calls Change

Top Sellers

1 -$6.16M
2 -$4.43M
3 -$2.56M
4
BlackRock
BlackRock
New York
-$1.71M
5
Goldman Sachs
Goldman Sachs
New York
-$1.65M
Name Holding Trade Value Shares
Change
Change in
Stake
26
$2.87M
27
$2.68M
28
$2.6M
29
$2.47M
30
$2.44M
31
$2.15M
32
$1.99M
33
$1.84M
34
$1.71M
35
$1.67M
36
$1.29M
37
$1.28M
38
$1.08M
39
$986K
40
$974K
41
$974K
42
$952K
43
$939K
44
$865K
45
$864K
46
$846K
47
$785K
48
$711K
49
$662K
50
$591K